| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| V Ryckmans, J P Kahn, S Modell, C Werner, R D McQuade, W Kerselaers, J Lissens, R Sanche. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. vol 42. issue 3. 2009-08-06. PMID:19452380. |
this study evaluated the safety/tolerability and effectiveness of aripiprazole titrated-dose versus fixed-dose switching strategies from risperidone in patients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues. |
2009-08-06 |
2023-08-12 |
Not clear |
| Taku Nagai, Rina Murai, Kanae Matsui, Hiroyuki Kamei, Yukihiro Noda, Hiroshi Furukawa, Toshitaka Nabeshim. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology. vol 202. issue 1-3. 2009-08-05. PMID:18679658. |
aripiprazole, an atypical antipsychotic drug, has been shown to improve disruption of prepulse inhibition and social interaction in an animal model of schizophrenia induced by phencyclidine (pcp); however, the effects of aripiprazole on recognition memory remain to be investigated. |
2009-08-05 |
2023-08-12 |
Not clear |
| Wen-Yu Hsu, Chien-I Lee, Nan-Ying Chiu, David A Kah. Aripiprazole in treatment-refractory schizophrenia. Journal of psychiatric practice. vol 15. issue 3. 2009-08-04. PMID:19461396. |
aripiprazole in treatment-refractory schizophrenia. |
2009-08-04 |
2023-08-12 |
Not clear |
| Wen-Yu Hsu, Chien-I Lee, Nan-Ying Chiu, David A Kah. Aripiprazole in treatment-refractory schizophrenia. Journal of psychiatric practice. vol 15. issue 3. 2009-08-04. PMID:19461396. |
this report describes the case of a 58-year-old female patient with treatment-refractory schizophrenia who was successfully switched from clozapine 300 mg/day to aripiprazole 20 mg/day because of changes in consciousness. |
2009-08-04 |
2023-08-12 |
Not clear |
| Robert G Stern, Theodore A Petti, Kurt Bopp, Anthony Tobi. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. Journal of clinical psychopharmacology. vol 29. issue 3. 2009-08-03. PMID:19440071. |
aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. |
2009-08-03 |
2023-08-12 |
Not clear |
| Robert G Stern, Theodore A Petti, Kurt Bopp, Anthony Tobi. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. Journal of clinical psychopharmacology. vol 29. issue 3. 2009-08-03. PMID:19440071. |
this open-label study tested the hypothesis that a switchover to aripiprazole would reduce the severity of social anxiety in patients, who have schizophrenia with co-occurring social anxiety, treated with neuroleptic medications. |
2009-08-03 |
2023-08-12 |
Not clear |
| Polash Shajahan, Sonia Keith, Chetan Majjiga, Jennifer Murphy, Alison MacRae, Muhammad Bashir, Mark Taylo. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study. The Journal of clinical psychiatry. vol 70. issue 5. 2009-07-22. PMID:19284930. |
comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study. |
2009-07-22 |
2023-08-12 |
Not clear |
| Anthony H Barnett, Helen L Millar, Jean-Yves Loze, Gilbert J L'Italien, Marc van Baardewijk, Martin Knap. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). European archives of psychiatry and clinical neuroscience. vol 259. issue 4. 2009-07-15. PMID:19267255. |
uk cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (star study). |
2009-07-15 |
2023-08-12 |
Not clear |
| Anthony H Barnett, Helen L Millar, Jean-Yves Loze, Gilbert J L'Italien, Marc van Baardewijk, Martin Knap. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). European archives of psychiatry and clinical neuroscience. vol 259. issue 4. 2009-07-15. PMID:19267255. |
assuming the risk of diabetes onset/chd events remained linear over 10 years, these risks were used to estimate the difference in direct and indirect cost consequences of diabetes and chd in schizophrenia patients treated with aripiprazole or soc over a 10-year period. |
2009-07-15 |
2023-08-12 |
Not clear |
| Anthony H Barnett, Helen L Millar, Jean-Yves Loze, Gilbert J L'Italien, Marc van Baardewijk, Martin Knap. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). European archives of psychiatry and clinical neuroscience. vol 259. issue 4. 2009-07-15. PMID:19267255. |
compared with soc, aripiprazole treatment may provide reductions in the health and economic burden to schizophrenia patients and health care services in the uk as a result of its favourable metabolic profile. |
2009-07-15 |
2023-08-12 |
Not clear |
| Michela Nosè, Simone Accordini, Paola Artioli, Francesco Barale, Corrado Barbui, Rossella Beneduce, Domenico Berardi, Gerardo Bertolazzi, Bruno Biancosino, Alfredo Bisogno, Raffaella Bivi, Filippo Bogetto, Marianna Boso, Alberto Bozzani, Piera Bucolo, Marcello Casale, Liliana Cascone, Luisa Ciammella, Alessia Cicolini, Gabriele Cipresso, Andrea Cipriani, Paola Colombo, Barbara Dal Santo, Michele De Francesco, Giorgio Di Lorenzo, Walter Di Munzio, Giuseppe Ducci, Arcadio Erlicher, Eleonora Esposito, Luigi Ferrannini, Farida Ferrato, Antonio Ferro, Nicoletta Fragomeno, Vincenzo Fricchione Parise, Maria Frova, Francesco Gardellin, Nicola Garzotto, Andrea Giambartolomei, Giancarlo Giupponi, Luigi Grassi, Natalia Grazian, Lorella Grecu, Gualtiero Guerrini, Francesco Laddomada, Ermanna Lazzarin, Camilla Lintas, Francesca Malchiodi, Lara Malvini, Livio Marchiaro, Alessandra Marsilio, Massimo Carlo Mauri, Antonio Mautone, Marco Menchetti, Giuseppe Migliorini, Marco Mollica, Daniele Moretti, Serena Mulè, Stylianos Nicholau, Flavio Nosè, Guglielmo Occhionero, Anna Maria Pacilli, Stefania Pecchioli, Mauro Percudani, Ennio Piantato, Carlo Piazza, Francesco Pontarollo, Roger Pycha, Roberto Quartesan, Luciana Rillosi, Francesco Risso, Raffella Rizzo, Paola Rocca, Stefania Roma, Matteo Rossattini, Giuseppe Rossi, Giovanni Rossi, Alessandra Sala, Claudio Santilli, Giuseppe Saraò, Antonio Sarnicola, Francesca Sartore, Silvio Scarone, Tiziana Sciarma, Alberto Siracusano, Stefania Strizzolo, Michele Tansella, Gino Targa, Annamarie Tasser, Rodolfo Tomasi, Rossana Travaglini, Antonio Veronese, Simona Zier. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials. vol 10. 2009-07-09. PMID:19445659. |
rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. |
2009-07-09 |
2023-08-12 |
Not clear |
| John M Kane, Olawale Osuntokun, Ludmila A Kryzhanovskaya, Wen Xu, Virginia L Stauffer, Susan B Watson, Alan Breie. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. The Journal of clinical psychiatry. vol 70. issue 4. 2009-06-30. PMID:19323965. |
a 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. |
2009-06-30 |
2023-08-12 |
Not clear |
| John M Kane, Olawale Osuntokun, Ludmila A Kryzhanovskaya, Wen Xu, Virginia L Stauffer, Susan B Watson, Alan Breie. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. The Journal of clinical psychiatry. vol 70. issue 4. 2009-06-30. PMID:19323965. |
to evaluate the effectiveness of olanzapine versus aripiprazole in patients with schizophrenia. |
2009-06-30 |
2023-08-12 |
Not clear |
| Shih-Fen Chen, Yu-Chih Shen, Chia-Hsiang Che. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Progress in neuro-psychopharmacology & biological psychiatry. vol 33. issue 3. 2009-06-16. PMID:19302829. |
we investigated whether the efficacy of aripiprazole can be predicted by a functional drd3 gene polymorphism ser9gly (rs6280) as modified by clinical factors in han chinese hospitalized patients with acutely exacerbated schizophrenia. |
2009-06-16 |
2023-08-12 |
Not clear |
| John W Newcomer, Jonathan M Meyer, Ross A Baker, James M Eudicone, Andrei Pikalov, Estelle Vester-Blokland, Robert D McQuade, David T Crandall, William H Carson, Ronald N Marcus, Gilbert L'italie. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophrenia research. vol 106. issue 2-3. 2009-06-10. PMID:18973991. |
this post-hoc analysis assessed changes in these parameters during treatment with the atypical antipsychotics olanzapine or aripiprazole using pooled data from three randomized, long-term clinical studies in patients with schizophrenia. |
2009-06-10 |
2023-08-12 |
Not clear |
| Virginia Stauffer, Haya Ascher-Svanum, Lin Liu, Tamara Ball, Robert Conle. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. BMC psychiatry. vol 9. 2009-06-10. PMID:19335905. |
this post-hoc analysis describes maintenance of response over 24 or 28 weeks in people treated for schizophrenia with olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole. |
2009-06-10 |
2023-08-12 |
Not clear |
| J Costenti. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole]. L'Encephale. vol 35. issue 1. 2009-06-01. PMID:19250996. |
on the other hand, the occupation by aripiprazole of the d2 receptors that are not stimulated by dopamine (on account of an insufficient presynaptic dopaminergic activity) restores a certain amount of stimulation, which partly alleviates negative expressions of schizophrenia. |
2009-06-01 |
2023-08-12 |
Not clear |
| W Wolfgang Fleischhacker, Robert D McQuade, Ronald N Marcus, Donald Archibald, René Swanink, William H Carso. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biological psychiatry. vol 65. issue 6. 2009-05-19. PMID:18986646. |
a double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. |
2009-05-19 |
2023-08-12 |
Not clear |
| Tim J R Lamber. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evidence-based mental health. vol 12. issue 2. 2009-04-27. PMID:19395609. |
switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. |
2009-04-27 |
2023-08-12 |
Not clear |
| Gary Remingto. Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms. Evidence-based mental health. vol 12. issue 2. 2009-04-27. PMID:19395610. |
refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms. |
2009-04-27 |
2023-08-12 |
Not clear |